Connect your AI

Merck & Co. MRK Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

Regeneron PharmaceuticalsREGN

$163.1M+169%

CytokineticsCYTK

$11.35M—

United TherapeuticsUTHR

$68.3M+311%

ImmunityBio, Inc.IBRX

$971K+341%

TRV

Trevi Therapeutics, Inc.TRVI

$222K-69.1%

Summit TherapeuticsSMMT

$3.8M+88.1%

Other financials

Income statement

Revenue$16.3B+4.9%

Gross profit$12.1B-0.2%

Net income-$4.2B-183%

EPS (diluted)-$1.72-186%

Balance sheet

Cash & equivalents$5.4B-38.2%

Total debt$49.1B+35.8%

Total equity$45.9B-5.1%

Total assets$128.69B+11.8%

Cash flow

Operating cash flow$3.9B+56.7%

CapEx$991.0M-25.4%

Free cash flow$2.9B+150%

Valuation

Market cap$317.37B+61.7%

Enterprise value$361.07B+60.4%

P/E35.5×+23.6×

P/S4.8×+1.7×

Profitability

Gross margin73.9%-2.5pp

Net margin13.6%-13.7pp

FCF margin21.5%-5.2pp

Returns & leverage

Return on equity19%-20.3pp

Debt / equity1.1×+0.3×

Current ratio1.3×-0.1×

Where this comes from

Reported directly by Merck & Co. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromStockOptionsExercised.

The official record: Merck & Co.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Merck & Co.'s stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Merck & Co.'s stock issuance proceeds?: Merck & Co. (MRK) reported stock issuance proceeds of $157M in Q1 2026.
How has Merck & Co.'s stock issuance proceeds changed year-over-year?: Merck & Co.'s stock issuance proceeds increased by 726.3% year-over-year, from $19M to $157M.
What is the long-term trend for Merck & Co.'s stock issuance proceeds?: Over 4 years (2021 to 2025), Merck & Co.'s stock issuance proceeds has grown at a -17.8% compound annual growth rate (CAGR), from $202M to $92M.
What does stock issuance proceeds mean?: Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.